Moleculin Biotech Inc.
(NASDAQ:MBRX) released updated blinded preliminary outcomes from Part A of its Phase 2/3 MIRACLE trial evaluating Annamycin with cytarabine for relapsed or refractory acute myeloid leukemia.
Concurrently, the biopharmaceutical enterprise announced the pricing of a public stock offering valued at 75 cents per share to fund its ongoing clinical programs.
The stock tanked after the company priced its $9.3 million public offering at a steep discount to the previous closing price, fueling investor concerns about dilution.
Preliminary MIRACLE Trial Results The latest trial data, covering 62 evaluable participants, showed a blinded complete remission rate of 24% and a composite complete remission rate of 37%.
